Deals In Depth: May 2014
Executive Summary
As Valeant continues its pursuit of Allergan, the spec pharma divested its aesthetics products to Galderma for $1.4 billion; Merck and Boston Scientific also sold off major OTC and interventional businesses, respectively. Biopharma funding was down from the previous month to just over $1 billion, while device financing was slightly up to $390 million.